Menu
Home
Conferences
Collections
Calls for Papers
MSF Research Ethics
About
My Saved Content
Science Portal
Advanced Search
My Saved Content
Browse All
Conferences
Collections
Calls for Papers
MSF Research Ethics
Clinical Case Reporting
About
English
24-week regimens for treatment of rifampicin-resistant tuberculosis: four-arm randomised trial | Conference Material / Video | MSF Science Portal
Conference Material
|
Video
24-week regimens for treatment of rifampicin-resistant tuberculosis: four-arm randomised trial
Berry C,
Motta I,
Kazounis E,
Fielding K,
Dodd M,
Nyang'wa BT,
Moodliar R
Save
Cite
Share
Save
Cite
Share
Similar Content
Abstract
|
Abstract
24-week regimens for treatment of rifampicin-resistant tuberculosis: four-arm randomised trial
2022 May 11 • MSF Scientific Days International 2022
Slide Presentation
|
Slide Presentation
24-week regimens for treatment of rifampicin-resistant tuberculosis: four-arm randomised trial
2022 May 11 • MSF Scientific Days International 2022
Loading...
Countries
Belarus
South Africa
Uzbekistan
Subject Area
antibiotic resistance
tuberculosis
antimicrobial resistance
Collections
TB-PRACTECAL Trial—Evidence for a shorter, safer, more effective treatment for drug-resistant tuberculosis
Languages
English
DOI
10.57740/atfr-ws57
Published Date
07 Jun 2022
Conference
MSF Scientific Days International 2022
Linked Content
Conference Material
|
Abstract
24-week regimens for treatment of rifampicin-resistant tuberculosis: four-arm randomised trial
2022 May 11 • MSF Scientific Days International 2022
Conference Material
|
Slide Presentation
24-week regimens for treatment of rifampicin-resistant tuberculosis: four-arm randomised trial
2022 May 11 • MSF Scientific Days International 2022
